{"id":13927,"date":"2023-12-08T10:44:24","date_gmt":"2023-12-08T01:44:24","guid":{"rendered":"https:\/\/www.emukk.com\/WP\/?p=13927"},"modified":"2024-09-18T07:15:01","modified_gmt":"2024-09-17T22:15:01","slug":"fda-announced-rapid-glycan-profiling-with-a-9-lectin-microarray-for-therapeutic-igg1-monoclonal-antibodies","status":"publish","type":"post","link":"https:\/\/www.emukk.com\/WP\/en\/fda-announced-rapid-glycan-profiling-with-a-9-lectin-microarray-for-therapeutic-igg1-monoclonal-antibodies\/","title":{"rendered":"FDA announced High-throughput Glycan Profiling Analysis with a 9-Lectin Microarray for Therapeutic IgG1 mAbs"},"content":{"rendered":"<p>To evaluate glycan epitopes of therapeutic IgG1 mAbs, FDA has developed a new lectin microarray with 9 kinds of lectins, and has demonstrated its effectiveness for high-throughput glycan profiling analysis using <a href=\"https:\/\/www.emukk.com\/WP\/en\/products-service-eng\/\">GlycoStation Reader 2300 (GSR2300) .<\/a><br \/>\n<a href=\"https:\/\/www.fda.gov\/science-research\/fda-science-forum\/rapid-glycan-profiling-nine-lectin-microarray-therapeutic-igg1-monoclonal-antibodies\">2023 FDA Science Forum<\/a><br \/>\n<a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2024.2304268\">Accepted paper\uff1aA tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies<\/a><br \/>\n<a href=\"https:\/\/www.fda.gov\/drugs\/regulatory-science-action\/novel-method-rapid-glycan-profiling-therapeutic-monoclonal-antibodies\">FDA Homepage Discription<\/a><br \/>\n<a href=\"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9240\">Accepted paper\uff1aLectin-Based Fluorescent Comparison of Glycan Profile\u2014FDA Validation to Expedite Approval of Biosimilars<\/a><\/p>\n<p>The new lectin microarray (IgG1-mAb-LecChip) developed by FDA immobilizes 9 kinds of lectins: rPhosL, rOTH3, RCA120, rMan2, MAL_I, rPSL1a, PHAE, rMOA, and PHEL, and uses <a href=\"https:\/\/www.emukk.com\/WP\/en\/products-service-eng\/standarization-of-glycan-analysis-technology\/\">a standard 14 wells LecChip format<\/a>.<br \/>\nGlycan analysis of IgG1 mAbs can be performed using lectin microarrays without creaving glycans, making it possible to perform high-throughput glycan profiling analysis from intact IgG1.<br \/>\nFDA has recommended pharmaceutical companies to use IgG1-mAb-LecChip and GlycoStation to facilitate high-throughput glycan profiling analysis when developing IgG1 mAbs to assess batch-to-batch or biosimilar-to-innovator glycan epitopes.<\/p>\n<p>The figure below shows how IgG1-mAb-LecChip, which was optimized for IgG1 glycan analysis, was developed using GlycoStation and LecChip (n=74 library).<\/p>\n<p><a href=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13923\" src=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-300x126.png\" alt=\"\" width=\"300\" height=\"126\" srcset=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-300x126.png 300w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-600x252.png 600w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-768x322.png 768w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-230x97.png 230w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-350x147.png 350w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip-480x202.png 480w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/IgG1-mAb-LecChip.png 979w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>As an example of showing the effectiveness of this technology, the figure below shows the result of evaluating the differences in glycosylation between Infliximab and its biosimilar using IgG1-mAB-LecChip and GSR2300. It can be clearly seen that there are significant differences in the abundance of High Mannose structure, sialic acid modification, and triantennary N-glycans.<\/p>\n<p><a href=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13977\" src=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-300x111.png\" alt=\"\" width=\"300\" height=\"111\" srcset=\"https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-300x111.png 300w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-600x222.png 600w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-768x284.png 768w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-230x85.png 230w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-350x129.png 350w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab-480x177.png 480w, https:\/\/www.emukk.com\/WP\/wp-content\/uploads\/2023\/12\/Infliximab.png 979w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>To evaluate glycan epitopes of therapeutic IgG1 mAbs, FDA has developed a new lectin microarray with 9 kinds o<\/p><\/div>\n<div class=\"blog-btn\"><a href=\"https:\/\/www.emukk.com\/WP\/en\/fda-announced-rapid-glycan-profiling-with-a-9-lectin-microarray-for-therapeutic-igg1-monoclonal-antibodies\/\" class=\"home-blog-btn\">\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-13927","post","type-post","status-publish","format-standard","hentry","category-technology-en"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/13927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/comments?post=13927"}],"version-history":[{"count":17,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/13927\/revisions"}],"predecessor-version":[{"id":13981,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/posts\/13927\/revisions\/13981"}],"wp:attachment":[{"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/media?parent=13927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/categories?post=13927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emukk.com\/WP\/wp-json\/wp\/v2\/tags?post=13927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}